Recherche
-
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials
(Nature Medicine. vol. 29, n° 6, pp. 1487-1499, 2023-06-01)Article de revueLibre accès -
Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
(Cells. vol. 12, n° 15, pp. 1927, 2023-07-25)Article de revueLibre accès -
Does food use disorder exist? Item response theory analyses of a food use disorder adapted from the DSM-5 substance use disorder criteria in a treatment seeking clinical sample
(Drug and Alcohol Dependence. vol. 251, 2023-10-01)Article de revue -
Camkiiβ in neuronal development and plasticity: An emerging candidate in brain diseases
(International Journal of Molecular Sciences. vol. 21, n° 19, pp. 1-15, 2020-10-01)Article de revueLibre accès -
Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study
(2020-08-15)Document de travail - Pré-publicationLibre accès -
Structural progression of Alzheimer's disease over decades: The MRI staging scheme
(Brain Communications. vol. 4, n° 3, 2022-04-28)Article de revueLibre accès -
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 6, 2023-09-22)Article de revueLibre accès -
Differential vulnerability of thalamic nuclei in multiple sclerosis
(Multiple Sclerosis Journal, 2022-08-12)Article de revueLibre accès -
Lifespan neurodegeneration of the human brain in multiple sclerosis
(Human Brain Mapping. vol. 44, n° 17, pp. 5602-5611, 2023-03-14)Article de revueLibre accès -
High B-value diffusion tensor imaging for early detection of hippocampal microstructural alteration in a mouse model of multiple sclerosis
(Scientific Reports. vol. 12, n° 1, pp. 12008, 2022-07-14)Article de revueLibre accès